Heart failure hope: Anti-Inflammatory drug may reduce need for dangerous heart meds
NCT ID NCT06062966
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether anakinra, a drug that blocks inflammation, can make the heart more sensitive to inotropes (medicines that strengthen heart contractions) in people with end-stage heart failure. If successful, patients might need lower, safer doses of inotropes. The study involves 20 adults on stable inotrope therapy and will measure changes in inflammation and medication needs over 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23284, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••